# Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

> **NCT07523282** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shenzhen MagicRNA Biotechnology Co., Ltd** · enrollment: 12 (estimated)

## Conditions studied

- Autoimmune Disease
- Systemic Lupus Erythematosus
- Systemic Sclerosis (SSc)

## Interventions

- **DRUG:** HN2302 Injection

## Key facts

- **NCT ID:** NCT07523282
- **Lead sponsor:** Shenzhen MagicRNA Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07523282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07523282, "Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07523282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*